InspireMD has announced that it has appointed Rick Olson, who was previously the director of international strategy and high performance management system at Covidien, as its new vice president of global sales operations. Olson will be responsible for fully implementing the global sales strategy the company has developed over the past several months.
A study in the Journal of Thoracic and Cardiovascular Surgery shows that minimally invasive surgical aortic valve replacement with a sutureless valve is associated with less paravalvular leak and reduced mortality compared with transcatheter aortic valve implantation (TAVI)—indicating that minimally invasive sutureless surgical aortic valve replacement could become the first-line therapy for patients in the grey area between TAVI and open surgical valve replacement.
Generating new cardiac muscle from human embryonic stem cells (hESCs) and/or induced pluripotent stem cells (iPSC) could fulfill the demand for therapeutic applications and drug testing. The production of a similar population of these cells remains a major limitation, but in a study published in Stem Cells Translational Medicine, researchers now believe they have found a way to do this.
A meta-analysis published in JAMA Internal Medicine indicates that percutaneous coronary intervention (PCI) does not reduce the risk of death or non-fatal myocardial infarction in patients with stable coronary artery disease with myocardial ischaemia that has been identified through stress testing or fractional flow reserve (FFR). These results raise questions about the effectiveness of ischaemia-driven revascularisation.
Transcatheter Technologies has revealed the successful 30-day follow-up results from a pilot study of its “truly prepositional” transcatheter aortic valve implantation (TAVI) system Trinity. The results show that the system is associated with a reduction in mean pressure gradient from 59mmHg at baseline to 20mmHG at 30 days post-implantation.
The American College of Cardiology (ACC), the American Association for Thoracic Surgery, the Society for Cardiovascular Angiography and Interventions, and The Society of Thoracic Surgeons have published a joint document on using transcatheter therapies to manage mitral regurgitation. The new document examines the responsible dissemination of these transcatheter therapies—specifically, it discusses the technologies’ critical components, operator training, protocols for care, and assessment of outcomes.
Sorin has announced that it has received the CE mark for the XL version of its Perceval bioprosthetic aortic valve, which is designed to replace a diseased native or malfunctioning prosthetic aortic valve using either traditional or minimally invasive heart surgery. This approval expands the Perceval portfolio, permitting cardiac surgeons to treat patients with annulus sizes ranging from 19mm to 27mm
Sorin has announced that its Solo Smart device, a stentless and biological aortic heart valve with no synthetic material, has received CE mark approval and has been implanted for the first time. A press release reports that the device is designed to respect the aortic root physiology and ensure a physiological blood flow through the valve annulus. It adds that this allows the Solo Smart valve to behave like a healthy native valve, thus restoring quality of life for patients.
Results from the Registre Français de la FFR, published in Circulation and presented at the American Heart Association annual meeting (16–20 November, Dallas, USA), indicates that a Fractional Flow Reserve (FFR)-guided revascularisation strategy that diverges from the strategy suggested by angiography does not increase the risk of major adverse cardiovascular events (MACE) at one year.
According to the XIMA (Xience or Vision stents for the management of angina in the elderly) study, the use of drug-eluting stents in patients aged ≥80 years is associated with less myocardial infarction and target vessel revascularisation than is the use of bare metal stents. Also, the longer use of dual antiplatelet therapy (DAPT) with drug-eluting stents is not associated with an increased risk of bleeding.
Boston Scientific has announced that, following CE mark approval, its Lotus transcatheter aortic valve implantation (TAVI) system has been used for the first time - two patients in Germany were implanted with the device.
A study published ahead of print in the Journal of the American College of Cardiology has found that the 99th percentile values for the high sensitivity cardiac troponin T (hs-cTnT) assay that is used to aid diagnosis of myocardial infarction are significantly higher in healthy men aged ≥50 years and healthy women aged ≥65 than the currently recommended cutoff value of 14ng/L—suggesting that using a universal cutoff value may lead to an over diagnosis of myocardial infarction.
The medical team leader of the FDA’s Division of Cardiovascular and Renal Products, Thomas A Marciniak, states in a clinical review of cangrelor (The Medicines Company) that the drug should not be recommended for reducing thrombotic cardiovascular events during percutaneous coronary intervention (PCI) because the studies supposedly supporting cangrelor for this indication are flawed and do not show superiority or non-inferiority of a cangrelor regimen compared with a clopidogrel (Plavix; Bristol-Myers Squibb, Sanofi-Aventis) regimen or with standard of care.
A report published recently provides evidence that the symptoms of depressive disorder are causally associated with the risk of coronary heart disease, and as such should be considered a potentially modifiable risk factor for the occurrence of coronary heart disease.
A study published recently in the Journal of the American Medical Association, reports that in an analysis of blood pressure patterns over a 25-year span from young adulthood to middle age, individuals who exhibited elevated and increasing blood pressure levels throughout this time period had greater odds of having higher measures of coronary artery calcification.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos